Search

everythinglearnresearchcommunity

for

Search:↓

Hair loss discussion includes potential HMI-115 treatment. Topical mucuna pruriens shows good results, blocking prolactin possibly more important than blocking DHT.

The user shared progress pictures after using oral minoxidil 2.5mg, oral finasteride 0.25mg three times a week, and weekly 1.5mm microneedling for two months. They reported positive results in hair growth.

The user experienced significant hair regrowth after one year of using oral minoxidil (2.5mg) and oral finasteride (1mg), with no side effects except initial shedding. The user noticed thicker eyebrows and beard, and the hairline improved with baby hairs, but the hair quality differs from the rest of the head.

A 21-year-old with diffuse thinning hair is considering RU58841 due to side effects from topical finasteride and is asking for the lowest effective dose and time to see results from RU58841 users.

The user experienced significant hair regrowth using a single pill containing 2.5mg minoxidil and 1mg finasteride over 11 months, with noticeable improvements starting around month 8. They reported minor side effects initially but none ongoing, and they have not undergone a hair transplant.

The user experienced significant hair regrowth using oral finasteride 1.25mg daily and a Capillus RX laser cap, with no side effects. Improvement was noticed after 9 months, and shedding stopped after the initial 4-5 months.

The user experienced hair growth using 5% topical Minoxidil foam twice daily from October 2024 to February 2025, without using finasteride due to family history of side effects. The user is considering other treatments like topical finasteride and received positive feedback on their progress.

Hair loss theory involves 3alpha-hydroxysteroid reductase (3AHD) converting DHT to androstenol. Discussion explores potential treatments and encourages more research.

The conversation is about future hair loss treatments. Current treatments mentioned include finasteride, minoxidil, and RU58841, with potential future treatments like GT20029, TDM-105795, JW0061, and follicle cloning.

Minoxidil may cause increased prolactin levels, leading to side effects like puffy nipples and chest tenderness. Users experienced these issues and considered stopping minoxidil while continuing or switching to other treatments like finasteride, microneedling, and supplements.

Verteporfin human clinical trials for hair loss may start in 2025. Additional resources and presentations are available for more information.

The user is using topical finasteride, minoxidil, nizoral shampoo, and microneedling for hair regrowth but hasn't seen results after 2-3 weeks. They added tretinoin to their routine and are advised to wait a few months for potential changes.

OP is using 5% minoxidil and a foligain supplement for hair loss, with blood test results showing high cortisol levels. OP is considering starting finasteride, while another user shares their experience with finasteride and hair loss challenges due to malabsorption issues.

User shared a 1-year update on finasteride, noting thicker hair but mild side effects like reduced libido and mild ED. Considering reducing the dose from 1mg to 0.5mg daily to alleviate side effects.

Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss. PP405 is still under evaluation for safety.

A user maintains NW2 hair with 1mg finasteride, 2.5mg oral minoxidil, and 5% topical minoxidil twice daily, along with ketoconazole shampoo and derma stamping. They seek advice on more aggressive treatments to achieve NW1.

PP405 is a topical gel being tested for hair regrowth in adults with androgenetic alopecia. Volunteers aged 18-55 are needed for a 16-week trial in several US locations.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Alfatradiol is suggested as another potential solution.

The conversation discusses using topical Melatonin for hair loss, which has shown an average increase in hair density of 41% in 6 months. The original poster is inquiring about others' experiences with Melatonin for this purpose.

Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.

A clinical trial for Verteporfin as a hair loss treatment, and the potential for greater progress in treatments for hair loss in the future. Common treatments such as Minoxidil, Finasteride and RU58841 were discussed.

The user experienced significant hair improvement after 4 months of using 1.25mg finasteride daily and 5% Minoxidil foam. They reported no side effects and no noticeable shedding phase.

A user reported significant hair thickening and new baby hairs on the hairline after 11 months of using 1mg finasteride every other day and microneedling once a week. They experienced no shedding, and finasteride stopped all hair loss within 24 hours of the first pill.

The user experienced sexual side effects from a topical finasteride and minoxidil combo and stopped using it after three weeks. They plan to use foam minoxidil nightly to slow hair loss and seek alternative treatments that don't affect sexual health.

GT20029 is discussed as a potential treatment for androgenetic hair loss by targeting androgen receptors, unlike finasteride which reduces DHT broadly. Concerns include its effectiveness, genetic variations in androgen receptors, and availability, with some skepticism about its potential as a true alternative.

The user is concerned about whether their hair styling is causing thinning or if it's natural. They are considering treatments like Minoxidil, finasteride, or RU58841 for hair loss.

The user plans to use 1% Koshine826, 0.1% Alfatradiol, Minoxidil with Tretinoin, microneedling, and Stemoxydine for hair loss treatment. They expect significant recovery with this regimen.

The conversation is about testing the effectiveness of RU58841 for hair loss, with the user planning to increase their dose to 30 mg per day along with 20 mg of Minoxidil. The test results showed approximately 70 mg/ml, which the user considers a good result.

The conversation discusses concerns about the potential risk of cancer from creating new hair follicles through microneedling, due to stem cell division. Specific treatments mentioned include microneedling, caffeine-containing anti-hair loss shampoos, and other unspecified topicals.

The conversation humorously discusses hair loss treatments, including minoxidil and finasteride, with a satirical suggestion of using fence castration as a natural finasteride for male deer. Participants joke about the side effects and effectiveness of these treatments.